KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $4.3 million.

  • Rigel Pharmaceuticals' Cash from Financing Activities rose 14339.57% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 15259.9%. This contributed to the annual value of -$11.6 million for FY2024, which is 16338.0% down from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Cash from Financing Activities of $4.3 million as of Q3 2025, which was up 14339.57% from $418000.0 recorded in Q2 2025.
  • Rigel Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $59.2 million during Q2 2021, with a 5-year trough of -$9.8 million in Q3 2024.
  • In the last 5 years, Rigel Pharmaceuticals' Cash from Financing Activities had a median value of $484000.0 in 2025 and averaged $4.3 million.
  • In the last 5 years, Rigel Pharmaceuticals' Cash from Financing Activities skyrocketed by 191131.39% in 2022 and then crashed by 103256.62% in 2024.
  • Rigel Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $1.1 million in 2021, then plummeted by 293.18% to -$2.1 million in 2022, then skyrocketed by 123.19% to $486000.0 in 2023, then soared by 201.44% to $1.5 million in 2024, then skyrocketed by 191.54% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $418000.0 for Q2 2025, and $484000.0 during Q1 2025.